Acoramidis

A survey of patients with CVD in Sweden revealed that of 78% of respondents cited a desire for information on sexual health, yet only 5% reported receiving this information.

BridgeBio Pharma announced that acoramidis, its small molecule stabilizer of transthyretin, has been approved by the FDA for the reduction of CV death and hospitalization in patients with transthyretin amyloid cardiomyopathy.

ATLANTA — Data from a small substudy with cardiac MRI suggest acoramidis may improve both cardiac mass and function for adults with symptomatic transthyretin amyloid cardiomyopathy, building on previous positive data, researchers reported.